Autism Spectrum Disorder Trial, Recruiting NCT06214065 Sponsor: Yale University Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT06214065
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People with an estimated full-scale IQ above 80
  • People who are right-handed
  • People who are fluent in English
  • People who are able to cooperate with all of the study's procedures
  • People with no history of neurological conditions (such as epilepsy) or brain surgery
  • People with no major medical conditions (such as cancer or heart failure)
  • People with no history of significant head injury
  • People with no close biological relatives who have a neurological condition that may be inherited, including epilepsy or multiple sclerosis (MS)
  • People who are not currently taking medications that affect mood, thinking, or brain activity (such as benzodiazepines, anti-seizure, or pro-convulsant medications)
  • People who are not currently using substances, as confirmed by a urine screen and breathalyzer test at each visit
  • Women who have a negative pregnancy test at the time of MRI scans
  • People with no reasons that would make an MRI scan unsafe for them (such as metal implants inside the body or severe claustrophobia)
  • People who have not previously taken part in a study in this lab that included a specific task called the Domino fMRI task
  • For people with ASD: Those who have been on a stable medication plan for at least 4 weeks before joining the study
  • For people in the control group: Those with no current or past psychiatric conditions (other than simple phobia), and no close biological relatives with ASD

Who may not be able to join:

  • No formal exclusion criteria were listed separately in the trial record; the inclusion criteria above describe the full set of requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Vaughn Steele, MD, Yale University

Phone: 860-545-7792

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
3 April 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mentalizing Task Related (MTR) neural activity in the mentalizing network

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov